Citius Pharmaceuticals

$1.83
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
+$0.01 (+0.55%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell CTXR and other stocks, options, and ETFs commission-free!

About CTXR

Citius Pharmaceuticals, Inc. Common Stock, also called Citius Pharmaceuticals, is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.

CEO
Myron Z. Holubiak
Employees
10
Headquarters
Cranford, New Jersey
Founded
2007
Market Cap
245.96M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
3.94M
High Today
$1.92
Low Today
$1.79
Open Price
$1.84
Volume
4.88M
52 Week High
$2.90
52 Week Low
$0.63

CTXR News

BenzingaApr 8

Exclusive: Citius Pharmaceuticals Exec Chairman On Product Pipeline, Potential $1B TAM

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Executive Chairman Leonard Mazur told Benzinga CEO Jason Raznick Thursday that he's invested $26.5 million of his own

CTXR Earnings

-$0.16
-$0.11
-$0.05
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected May 13, Pre-Market

You May Also Like

SWBK+
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure